# OnCo record siltuximab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/siltuximab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "siltuximab" ;
  schema:name "Siltuximab"@en ;
  schema:description "Siltuximab (Sylvant) is an antibody that neutralises the inflammatory messenger interleukin-6. It is the only approved treatment for multicentric Castleman disease, a rare lymph node disorder, in people without HIV or HHV-8 infection."@en ;
  schema:url <https://onco.cc/drugs/siltuximab/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Siltuximab> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=siltuximab>, <https://www.cancer.gov/about-cancer/treatment/drugs/siltuximab>, <https://www.ema.europa.eu/en/medicines/human/EPAR/sylvant> ;
  onco:status "approved" ;
  onco:tag "nci-list" ;
  onco:modality "Monoclonal antibody (anti-IL-6, chimeric IgG1)" ;
  schema:alternateName "Sylvant" ;
  onco:approval "US 2014: Multicentric Castleman disease in HIV-negative and HHV-8-negative patients", "EU 2014: Multicentric Castleman disease in HIV-negative and HHV-8-negative adults" ;
  onco:related <https://onco.cc/drugs/tocilizumab/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/il6/> ;
  onco:companies <https://onco.cc/companies/recordati/>, <https://onco.cc/companies/johnson-johnson/> ;
  onco:trials <https://onco.cc/trials/nct07570173/>, <https://onco.cc/trials/nct06679829/>, <https://onco.cc/trials/nct03315026/> .